European Penny Stocks To Watch In September 2026

European markets have shown mixed performance recently, with the pan-European STOXX Europe 600 Index ending the week slightly up amid fluctuating investor sentiment driven by economic data and geopolitical developments. Penny stocks, while an older term, continue to capture attention as they represent smaller or newer companies that can offer growth potential at lower price points. By focusing on those with strong balance sheets and solid fundamentals, investors may uncover opportunities in this often-overlooked segment of the market.

Underneath we present a selection of stocks filtered out by our screen.

Inmocemento (BME:IMC)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Inmocemento, S.A. operates in the cement and real estate sectors across Spain, the United Kingdom, Tunisia, the United States, and internationally with a market capitalization of approximately €1.78 billion.

Operations: The company generates revenue from two main segments: Cements, contributing €682.07 million, and Real Estate, accounting for €354.32 million.

Market Cap: €1.78B

Inmocemento, S.A. reported half-year sales of €516.41 million, up from €446.36 million a year prior, though net income fell to €151.16 million from €232.88 million. Despite high-quality past earnings and satisfactory debt levels with a net debt to equity ratio of 4.4%, the company faces challenges including negative earnings growth over the past year and lower profit margins compared to last year (25.4% vs 32.2%). While trading significantly below estimated fair value, its share price remains volatile, and its return on equity is relatively low at 9.2%.

• Navigate through the intricacies of Inmocemento with our comprehensive balance sheet health report here.
• Review our growth performance report to gain insights into Inmocemento's future.

Adocia (ENXTPA:ADOC)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Adocia SA is a clinical-stage biotechnology company focused on researching and developing therapeutic solutions for diabetes and obesity, with a market cap of €80.69 million.

Operations: The company generates revenue from its Regenerative Medicine for the Treatment of Chronic Diseases segment, amounting to €3.85 million.

Market Cap: €80.69M

Adocia's market cap stands at €80.69 million, with revenue from regenerative medicine reaching €3.85 million, yet it remains unprofitable and is not expected to achieve profitability in the next three years. The company has a cash runway of less than a year if free cash flow continues to grow modestly. Recent board changes bring experienced leadership with Maureen Deehan and Suman Shirodkar joining in strategic roles, potentially strengthening governance. Adocia retains global rights for M1Pram after Sanofi's exclusivity ended but has paused its development amid evolving diabetes treatment landscapes and limited financial resources.

• Take a closer look at Adocia's potential here in our financial health report.
• Understand Adocia's earnings outlook by examining our growth report.

7C Solarparken (XTRA:HRPK)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: 7C Solarparken AG focuses on the production and sale of electricity in Germany and Belgium, with a market cap of €133.18 million.

Operations: The company generates revenue primarily through the sale of electricity, amounting to €65.67 million.

Market Cap: €133.18M

7C Solarparken's market cap is €133.18 million, with revenue from electricity sales reaching €65.67 million, indicating it is not pre-revenue. Despite declining earnings at 33.8% annually over the past five years and current unprofitability, the company maintains a seasoned management team with an average tenure of 12.3 years and an experienced board averaging 9.2 years. Interest payments are well covered by EBIT (3.8x), although net debt to equity remains high at 42.8%. Short-term assets (€91.2M) exceed short-term liabilities (€38.4M), but long-term liabilities (€238.9M) are not fully covered, indicating financial challenges ahead.

• Get an in-depth perspective on 7C Solarparken's performance by reading our balance sheet health report here.
• Gain insights into 7C Solarparken's future direction by reviewing our growth report.

Where To Now?

• Click through to start exploring the rest of the 306 European Penny Stocks now.
• Seeking Other Investments? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com